Baricitinib effectively regrows hair in severe alopecia areata cases.
September 2025 in “Tạp chí Da liễu học Việt Nam” Combining oral methylprednisolone with microneedle radiofrequency improves hair growth in alopecia areata but may cause pain and side effects.
July 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is generally safe for alopecia areata patients over 72 months.
July 2025 in “Pakistan Journal of Intensive Care Medicine” Clobetasol propionate 0.05% ointment is more effective than tacrolimus 0.1% ointment for treating alopecia areata.
July 2025 in “International Journal of Dermatology Venereology and Leprosy Sciences” Microneedling can effectively promote hair regrowth in alopecia areata.
April 2025 in “PharmacoEconomics - Open” Patients with Alopecia Areata are willing to trade life duration for better quality of life.
March 2025 in “SKIN The Journal of Cutaneous Medicine” Certain patient characteristics can help predict hair regrowth success with ritlecitinib in alopecia areata.
The treatment showed promising hair regrowth in advanced-stage hair loss.
January 2025 in “Balkan Medical Journal” Baricitinib helps regrow hair in severe alopecia areata and is safe, but more research is needed.
January 2025 in “Acta Dermatovenerologica Alpina Pannonica et Adriatica” Baricitinib is effective and safe for treating severe alopecia areata.
August 2024 in “JAMA Dermatology” Continuous baricitinib is needed to keep hair regrowth in severe alopecia areata.
June 2024 in “Dermatology and Therapy” Baricitinib improves quality of life and reduces anxiety and depression in severe alopecia areata patients with hair regrowth.
Baricitinib shows promise for treating alopecia areata with mild side effects.
Low-dose oral minoxidil is generally safe for treating hair loss, with mostly mild side effects.
December 2023 in “Research Square (Research Square)” These specific gene polymorphisms are not linked to Alopecia Areata in Egyptians.
October 2023 in “Frontiers in medicine” Comprehensive screening for infections is crucial before starting JAK inhibitors in alopecia areata patients.
October 2023 in “Dermatologie pro praxi” Alopecia areata causes hair loss and has various treatment options, but responses differ.
September 2023 in “Dermatology and therapy” Ritlecitinib effectively improves hair growth in alopecia areata patients, regardless of hair loss pattern.
March 2023 in “PARIPEX INDIAN JOURNAL OF RESEARCH” Tofacitinib helped regrow hair in most patients with severe hair loss.
March 2022 in “Nepal Journal of Dermatology Venereology & Leprology” Methotrexate with steroids is slightly more effective than azathioprine with steroids for treating severe alopecia areata.
November 2020 in “Dubai medical journal” Tofacitinib may effectively regrow hair in alopecia totalis patients.
April 2016 in “Journal of The American Academy of Dermatology” Certain scalp tissue features can predict how well alopecia areata responds to steroid injections.
May 2015 in “Journal of The American Academy of Dermatology” Both treatments help with hair regrowth in alopecia areata, but azathioprine has milder side effects than betamethasone.
10 citations
,
December 2020 in “Dermatologic Therapy” Minoxidil and spironolactone combo effectively treats androgenetic alopecia, improving hair density and diameter.
67 citations
,
April 2018 in “JAMA Dermatology” Hair loss from hormone therapy in breast cancer patients can be improved with minoxidil treatment.
39 citations
,
January 2012 in “International Journal of Trichology” Melatonin solution helps treat hair loss in men and women.
2 citations
,
November 2017 in “Cardiovascular endocrinology” Early balding, premature graying, and hair thinning can predict heart disease in young Asian males.
October 2025 in “Frontiers in Medicine” The minoxidil-finasteride combination is more effective for hair growth than minoxidil alone.
July 2025 in “Current Treatment Options in Oncology” Scalp cooling helps prevent hair loss during chemotherapy, and minoxidil aids regrowth.
Androgenetic alopecia is not linked to higher risks of hypertension or hyperaldosteronism.